Lilly’s Covid-19 Antibody Treatment Is Authorized For Child Use

Lilly’s Covid-19 Antibody Treatment Is Authorized For Child Use
SHARE

There are all kinds of viable treatments in the works for the novel coronavirus-triggered disease, and the latest one that we are addressing is from Lilly. 

It’s been just revealed by The Wall Street Journal that Eli Lilly & Co.’s monoclonal antibody drug has been cleared for emergency use in children under the age of 12, the Food and Drug Administration said on Friday.

The same online publication notes the following:

“the authorization is the first for an antibody drug to treat young children, including newborns, who have tested positive for Covid-19 or been exposed to the virus and who are at high risk of developing severe cases including hospitalization or death.”

Pfizer covid pill new details are here 

The other day, we were revealing that Mikael Dolsten, Pfizer’s chief scientific officer, says that during the SARS outbreak in 2003, company scientists had begun to search for ways to combat that coronavirus.

In particular, they looked for proteins crucial for the virus to replicate once it infected someone. Pfizer focused on protein virus needs for replication, according to the publication. 
One viral protein they focused on is called a protease.

“We have learned that protease is a key regulator for the virus to unleash its machinery and hijack the human cells,” Dolsten said. 

The same article notes that this was just the start, and the observations found back then are helping the treatments today. Check out more details in the original notes. 

The Omicron covid variant has been making headlines a lot lately. Check out the latest reports that have been revealed by The Wall Street Journal.

pixabay.com

It’s been revealed that early laboratory studies suggest that a Covid-19 antibody treatment developed by GlaxoSmithKline PLC and Vir Biotechnology Inc. is effective against the Omicron variant.

Stay tuned for more relevant news, and make sure to stay safe as well during these difficult times in which we are living. 


SHARE
Rada Mateescu

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she's covering the latest news on these niches.

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.